Latest Ratios: P/E Ratio -39.3x · EV/EBITDA N/A · ROE -92.1%. (2020–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $1.7B | $1.2B | $27M | — | — | — | — |
| Enterprise Value | $1.7B | $1.1B | $-56890000 | — | — | — | — |
| P/E Ratio → | -39.27 | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — |
| P/B Ratio | 58.58 | 42.09 | 0.43 | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | 89.3% | 92.5% | 100.0% |
| Operating Margin | — | — | — | — | -167.8% | -165.0% | -115.7% |
| Net Profit Margin | — | — | — | — | -128.5% | -145.6% | -127.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | -92.1% | -92.1% | -59.4% | — | -241.3% | -90.1% | -120.0% |
| ROA | -56.5% | -56.5% | -36.4% | 155.3% | -39.1% | -29.8% | -35.5% |
| ROIC | — | — | — | — | — | — | — |
| ROCE | -62.1% | -62.1% | -34.6% | -149.0% | -76.4% | -50.3% | -40.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | — | — | — | 0.29 | 0.55 |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -2.05 | -1.34 | — | — | -2.03 | -1.72 |
| Net Debt / EBITDA | — | — | — | -0.39 | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | -6.17 | -6.17 | -3.04 | — | — | — | — |
Net cash position: cash ($58M) exceeds total debt ($633000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 5.20 | 5.20 | 7.33 | 3.20 | 2.86 | 2.52 | 3.42 |
| Quick Ratio | 5.20 | 5.20 | 7.33 | 3.20 | 2.86 | 2.52 | 3.42 |
| Cash Ratio | 5.11 | 5.11 | 6.94 | 3.11 | 2.78 | 2.33 | 3.18 |
| Asset Turnover | — | — | — | — | 1.57 | 0.20 | 0.28 |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | 38.49 | 21.24 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $11M | $2M | $1M | $930352 | $806837 | $681012 |
Clinical trial funding dependency
As reported in recent financial statements, PVLA trades at a price-to-book ratio of 59.59, a valuation level that suggests investors are pricing in the potential success of the QTORIN platform rather than current tangible assets or any near-term earnings potential within the biotechnology sector.
The extreme P/B multiple indicates that the market is assigning significant intangible value to the company's intellectual property and clinical pipeline. This valuation is highly sensitive to clinical trial outcomes, as the absence of revenue makes traditional P/E or EV/EBITDA metrics effectively meaningless for assessing the company's fundamental worth.
Based on historical data, the company's return on equity has remained deeply negative, reaching -12.1% in 2026Q1, which reflects the ongoing destruction of shareholder capital as the firm prioritizes high-cost clinical development over the generation of positive returns on invested capital.
The persistent negative ROE is a structural consequence of the company's pre-revenue status and heavy R&D spending. Investors should monitor whether the company can eventually pivot toward a positive return profile once the QTORIN gel moves from clinical testing to commercialization, though current trends suggest continued capital intensity.
According to the latest quarterly filings, the company maintains a current ratio of 28.88, a figure that appears robust on the surface but masks the reality that the firm is rapidly consuming its cash reserves to fund late-stage clinical trials for its lead therapeutic candidate.
While the high current ratio suggests no immediate solvency risk, the lack of revenue means that liquidity is entirely dependent on the existing cash balance. Any unforeseen delays in the Phase 3 MLM trial could force the company to seek dilutive financing, potentially undermining the current liquidity position.
As indicated by the provided financial data, the company maintains a debt-to-equity ratio of 0.00 as of 2026Q1, suggesting that management has avoided traditional debt financing in favor of equity-based capital, which preserves the balance sheet from interest obligations but increases the risk of shareholder dilution.
The absence of debt is a prudent strategy for a clinical-stage firm, as it avoids the risk of default during the high-burn development phase. However, the negative interest coverage ratio of -7.29 highlights that the company's operating losses are the primary driver of financial strain, rather than debt service requirements.
Based on an analysis of the company's financial structure, the current ratio is the most commonly misapplied metric, as it suggests a level of financial health that is misleading for a pre-revenue entity that lacks the operational cash flow to sustain its long-term research requirements.
Investors often mistake a high current ratio for operational stability, ignoring the fact that the company's cash is a finite resource being depleted by R&D. A more appropriate metric for this business model would be the 'cash burn rate' relative to the 'time-to-milestone,' which better captures the true risk of capital exhaustion.
Includes 30+ ratios · 6 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PVLA stock.
Palvella Therapeutics, Inc.'s current P/E ratio is -39.3x. This places it at the 50th percentile of its historical range.
Palvella Therapeutics, Inc.'s return on equity (ROE) is -92.1%. The historical average is -120.6%.
Based on historical data, Palvella Therapeutics, Inc. is trading at a P/E of -39.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.